Eli Lilly and Company News Releases https://investor.lilly.com/ Eli Lilly and Company News Releases en Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology https://investor.lilly.com/news-releases/news-release-details/lilly-presents-positive-results-taltzr-ixekizumab-vs-humirar INDIANAPOLIS , June 14, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA) as a late-breaking abstract at the European Congress Fri, 14 Jun 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41451 Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology https://investor.lilly.com/news-releases/news-release-details/lilly-present-5-year-sustained-efficacy-and-safety-results INDIANAPOLIS , June 11, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today the company will present positive, five-year Phase 3 data for Taltz ® (ixekizumab). Patients with moderate- to severe plaque psoriasis who continued to receive Taltz maintained high levels of skin Tue, 11 Jun 2019 03:00:00 -0400 Eli Lilly and Company News Releases 41446 Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta® https://investor.lilly.com/news-releases/news-release-details/detailed-findings-carolinar-outcome-trial-support-long-term - CAROLINA® demonstrated no increased cardiovascular risk for Tradjenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor - Adults with diabetes treated with Tradjenta experienced fewer events of hypoglycemia Mon, 10 Jun 2019 21:30:00 -0400 Eli Lilly and Company News Releases 41441 New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria https://investor.lilly.com/news-releases/news-release-details/new-analysis-shows-cardiorenal-risk-reductions-jardiancer-are - Findings from an EMPA-REG OUTCOME® post-hoc analysis of adults with chronic kidney disease without overt proteinuria presented at American Diabetes Association's 79th Scientific Sessions® RIDGEFIELD , Conn. and INDIANAPOLIS , June 10, 2019 /PRNewswire/ -- A new post-hoc analysis of data from the Mon, 10 Jun 2019 13:00:00 -0400 Eli Lilly and Company News Releases 41436 Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes https://investor.lilly.com/news-releases/news-release-details/trulicityr-dulaglutide-significantly-reduced-major REWIND data showed a consistent effect in people with and without established cardiovascular disease INDIANAPOLIS , June 9, 2019 /PRNewswire/ -- Detailed results from REWIND, the Trulicity ® (dulaglutide) cardiovascular outcome trial, showed a significant 12 percent reduction in major Sun, 09 Jun 2019 19:30:00 -0400 Eli Lilly and Company News Releases 41426 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions https://investor.lilly.com/news-releases/news-release-details/lillys-ultra-rapid-lispro-provided-similar-a1c-reductions Pivotal phase 3 data in people with type 1 and type 2 diabetes presented at the American Diabetes Association's® 79th Scientific Sessions® INDIANAPOLIS , June 9, 2019 /PRNewswire/ -- Two phase 3 studies show that Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro Sun, 09 Jun 2019 11:30:00 -0400 Eli Lilly and Company News Releases 41421 Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79ᵗʰ Scientific Sessions® https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-demonstrates-benefits-data-presented-american INDIANAPOLIS , June 8, 2019 /PRNewswire/ -- Results from several studies of  Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist (RA), tirzepatide, reinforce its potential in lowering A1C and body weight in people with type 2 diabetes. Sat, 08 Jun 2019 20:30:00 -0400 Eli Lilly and Company News Releases 41416 Lilly to Present New Data and Commitment to Patient-Centered Solutions at the Annual European Congress of Rheumatology https://investor.lilly.com/news-releases/news-release-details/lilly-present-new-data-and-commitment-patient-centered-solutions - Thirty abstracts will reflect investigations into the treatment of a broad range of rheumatic diseases - INDIANAPOLIS , June 6, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will present data for Taltz ® (ixekizumab) and Olumiant ® (baricitinib) at the Annual European Congress of Thu, 06 Jun 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41411 Lilly to Showcase Scientific Innovation within Dermatology Portfolio at 24th World Congress of Dermatology https://investor.lilly.com/news-releases/news-release-details/lilly-showcase-scientific-innovation-within-dermatology - Eighteen abstracts will reveal new insights for the management of moderate-to-severe plaque psoriasis and psoriatic arthritis, as well as the potential treatment of moderate-to-severe atopic dermatitis and alopecia areata - INDIANAPOLIS , June 5, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: Wed, 05 Jun 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41401 FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks https://investor.lilly.com/news-releases/news-release-details/fda-approves-emgalityr-galcanezumab-gnlm-first-and-only -With this approval, Emgality is the only calcitonin gene-related peptide (CGRP) antibody indicated for the preventive treatment of migraine and the treatment of episodic cluster headache[1] INDIANAPOLIS , June 4, 2019 /PRNewswire/ --   Eli Lilly and Company (NYSE: LLY) announced today that the Tue, 04 Jun 2019 21:01:00 -0400 Eli Lilly and Company News Releases 41396 U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes https://investor.lilly.com/news-releases/news-release-details/us-fda-accepts-new-drug-application-triple-combination-tablet RIDGEFIELD , Conn. and INDIANAPOLIS , June 4, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration ( FDA ) has accepted the New Drug Application (NDA) for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended release (XR) for the treatment of Tue, 04 Jun 2019 07:30:00 -0400 Eli Lilly and Company News Releases 41386 Lilly's Lower-Priced Insulin Now Available https://investor.lilly.com/news-releases/news-release-details/lillys-lower-priced-insulin-now-available List price of Lilly's Insulin Lispro Injection 50 percent less than branded Humalog INDIANAPOLIS , May 22, 2019 /PRNewswire/ --  Eli Lilly and Company's (NYSE: LLY) Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly's rapid-acting insulin and need a Wed, 22 May 2019 06:30:00 -0400 Eli Lilly and Company News Releases 41336 Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions https://investor.lilly.com/news-releases/news-release-details/lillys-mirikizumab-met-primary-endpoint-and-key-secondary The safety and efficacy data from the induction period of the Phase 2 trial encourage Lilly to initiate a Phase 3 trial for mirikizumab for the treatment of Crohn's disease later this year INDIANAPOLIS , May 21, 2019 /PRNewswire/ -- In an oral presentation from the Digestive Disease Week medical Tue, 21 May 2019 13:15:00 -0400 Eli Lilly and Company News Releases 41331 Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer https://investor.lilly.com/news-releases/news-release-details/data-presentations-asco-2019-highlight-lillys-targeted-approach Lung cancer highlights to include the first presentation of RELAY results and additional findings from KEYNOTE-189 Lilly to share data from Phase 3 ANNOUNCE trial in people with advanced soft tissue sarcoma INDIANAPOLIS , May 15, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today Wed, 15 May 2019 17:00:00 -0400 Eli Lilly and Company News Releases 41311 Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma https://investor.lilly.com/news-releases/news-release-details/lillys-cyramzar-ramucirumab-becomes-first-fda-approved-biomarker This new indication - the fifth FDA approval for CYRAMZA in an advanced or metastatic cancer - is for the second-line treatment of patients with hepatocellular carcinoma (HCC) who are AFP-High (AFP ≥400 ng/mL) Approximately forty percent of all patients with advanced HCC are AFP-High and are a Mon, 13 May 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41301 AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience https://investor.lilly.com/news-releases/news-release-details/aan-2019-two-new-analyses-lasmiditan-phase-3-studies-measured - The lasmiditan Phase 3 program encompassed more than 4,000 patients and 20,000 migraine attacks[1,2,3] INDIANAPOLIS , May 8, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced new data and post-hoc analyses for lasmiditan, an investigational, oral, first-in-class molecule for Wed, 08 May 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41286 AAN 2019: Pooled Analyses of Two Emgality® (galcanezumab-gnlm) Phase 3 Studies Show Reduction in Monthly Migraine Headache Days in Low- and High-Frequency Episodic Migraine Subgroups https://investor.lilly.com/news-releases/news-release-details/aan-2019-pooled-analyses-two-emgalityr-galcanezumab-gnlm-phase-3 INDIANAPOLIS , May 6, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of results from pooled subgroup analyses of efficacy data from the Phase 3 EVOLVE-1 and EVOLVE-2 studies. These analyses demonstrate a reduction in monthly migraine headache days Mon, 06 May 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41261 Lilly to Present New Data at AAN 2019 on Emgality® (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders Portfolio https://investor.lilly.com/news-releases/news-release-details/lilly-present-new-data-aan-2019-emgalityr-galcanezumab-gnlm-and - 19 abstracts to be presented, including Phase 3, eight-week data on Emgality for the preventive treatment of episodic cluster headache in adults, featured in a plenary presentation - First-time presentation of lasmiditan clinical data on the onset of response for the acute treatment of migraine Thu, 02 May 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41231 Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market https://investor.lilly.com/news-releases/news-release-details/lilly-establish-access-program-patients-it-prepares-withdraw Lilly is working to ensure current patients access to Lartruvo with limited interruption after it is withdrawn from the market INDIANAPOLIS , April 25, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that the company has been working to facilitate the withdrawal of Lartruvo® Thu, 25 Apr 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41196 Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis https://investor.lilly.com/news-releases/news-release-details/lilly-announces-positive-top-line-results-coast-x-52-week INDIANAPOLIS , April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz ®  (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of non-radiographic axial Mon, 22 Apr 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41171 Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis https://investor.lilly.com/news-releases/news-release-details/pfizer-and-lilly-announce-top-line-results-long-term-phase-3 NEW YORK & INDIANAPOLIS--( BUSINESS WIRE )--Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab Thu, 18 Apr 2019 17:30:00 -0400 Eli Lilly and Company News Releases 41161 Survey Reveals Genital Psoriasis May Reduce Patients’ Self-Confidence and Hinder Them from Having Close Relationships https://investor.lilly.com/news-releases/news-release-details/survey-reveals-genital-psoriasis-may-reduce-patients-self INDIANAPOLIS, March 21, 2019 – Eli Lilly and Company (NYSE:LLY) announced today findings from a quantitative opinion survey, which found that people with genital psoriasis can experience reduced self-confidence and struggle to have close relationships. Thu, 21 Mar 2019 21:00:00 -0400 Eli Lilly and Company News Releases 41041 NCCN Announces Six Quality Improvement Projects in Gastric Cancer Care Approved for Collaboration with Lilly Oncology https://investor.lilly.com/news-releases/news-release-details/nccn-announces-six-quality-improvement-projects-gastric-cancer PLYMOUTH MEETING, Pa. and INDIANAPOLIS , March 20, 2019 /PRNewswire/ -- The National Comprehensive Cancer Network ® ( NCCN ® ) Oncology Research Program ( ORP ) and Eli Lilly and Company (NYSE: LLY) today announced six projects that aim to improve the delivery of gastric and gastroesophageal Wed, 20 Mar 2019 08:45:00 -0400 Eli Lilly and Company News Releases 41011 Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer https://investor.lilly.com/news-releases/news-release-details/lillys-cyramzar-ramucirumab-phase-3-relay-trial-met-primary Global, randomized, placebo-controlled study confirms CYRAMZA, in combination with erlotinib, significantly delayed disease progression in previously untreated patients with metastatic non-small cell lung cancer whose tumors have activating EGFR mutations Global regulatory submissions to be Tue, 12 Mar 2019 06:45:00 -0400 Eli Lilly and Company News Releases 40981 Lilly Receives FDA Priority Review Designation for Emgality® (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults https://investor.lilly.com/news-releases/news-release-details/lilly-receives-fda-priority-review-designation-emgalityr INDIANAPOLIS , March 5, 2019 /PRNewswire/ --   Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration ( FDA ) has granted Priority Review for its supplemental Biologics License Application (sBLA) for Emgality ® (galcanezumab-gnlm) injection for the preventive Tue, 05 Mar 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40896 Lilly to Introduce Lower-Priced Insulin https://investor.lilly.com/news-releases/news-release-details/lilly-introduce-lower-priced-insulin Authorized generic version of Humalog will be available in U.S. pharmacies at 50 percent lower list price INDIANAPOLIS , March 4, 2019 /PRNewswire/ -- Reinforcing our commitment to lower out-of-pocket costs for people who need insulin, Eli Lilly and Company (NYSE: LLY) today announced we will Mon, 04 Mar 2019 06:30:00 -0500 Eli Lilly and Company News Releases 40881 Lilly to Present Data Demonstrating Continued Scientific Advancements in Broad Dermatology Portfolio at AAD Annual Meeting https://investor.lilly.com/news-releases/news-release-details/lilly-present-data-demonstrating-continued-scientific - Over 25 abstracts for medicines in Lilly's dermatology portfolio, including Taltz® (ixekizumab), highlight new findings for the treatment of patients with moderate-to-severe plaque psoriasis, including genital psoriasis and active psoriatic arthritis - INDIANAPOLIS , March 1, 2019 /PRNewswire/ Fri, 01 Mar 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40866 Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain https://investor.lilly.com/news-releases/news-release-details/pfizer-and-lilly-announce-top-line-results-phase-3-study NEW YORK and INDIANAPOLIS , Feb. 19, 2019 /PRNewswire/ --  Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP). Tue, 19 Feb 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40686 Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride https://investor.lilly.com/news-releases/news-release-details/boehringer-ingelheim-and-lilly-announce-carolinar-cardiovascular - Tradjenta (linagliptin) demonstrated no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk - With a median follow-up of more than 6 years, CAROLINA adds evidence to the long-term safety profile of Tradjenta RIDGEFIELD, Conn. Thu, 14 Feb 2019 06:30:00 -0500 Eli Lilly and Company News Releases 40641 Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis https://investor.lilly.com/news-releases/news-release-details/lilly-announces-top-line-phase-3-results-baricitinib-patients INDIANAPOLIS , Feb. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the Mon, 04 Feb 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40321